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 ABBREVIATIONS 
CRF  - Chronic renal failure 
 
ESRD  - End stage renal disease 
 
TG  - Triglyceride 
 
TC  - Total cholesterol 
 
HDL  - High density lipoprotein 
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ABCA1 - ATP binding  cassette transporter type 1
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INTRODUCTION 
Chronic  renal  failure  (CRF) results in profound lipid disorders, which 
stem largely from dysregulation of high-density lipoprotein (HDL) and 
triglyceride-rich lipoprotein metabolism .Together, these abnormalities may 
contribute to the risk of  arteriosclerotic cardiovascular disease and may 
adversely affect progression of renal  disease and energy metabolism in CRF. 
Cardiovascular disease (CVD) is the leading cause of death among 
patients with chronic and end-stage renal disease (ESRD). There is growing 
evidence that cardiovascular damage begins as soon as the kidney loses 
function and increases in severity during the progression of kidney disease. 
Hypertension and diabetes mellitus, known risk factors for the development of 
CVD in the general population, are also the most common causes for the 
development of CVD in patients with CRF and ESRD. It is known that patients 
with type 2 diabetes who require dialysis are about 30 times more likely to die 
of CVD, including heart attacks and strokes, than the general population. 
 There are several other important risk factors, such as smoking, 
proteinuria and dyslipidemia that independently or in combination with 
elevated blood pressure, can cause deterioration in renal function. 
Abnormalities in lipid metabolism and dyslipidemia are known to contribute to 
glomerulosclerosis and are common in renal disease. In addition, post-
transplant dyslipidemias have been associated with an increased risk of 
ischemic heart disease and have been shown to increase risk of chronic 
rejection, altered graft function and mortality. However, only recently, trials are 
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starting to evaluate if reversal of dyslipidemia can actually lead to a decreased 
risk of CVD in patients with chronic renal conditions. 
         Various studies have been done to describe the characteristic features of 
lipoprotein metabolism during different stages of renal insufficiency and to 
describe the possible links between the underlying lipid transport abnormalities 
and the pathophysiology of lipoprotein abnormalities in patients with chronic 
renal failure. Similar abnormalities of lipid profile are found in chronic renal 
failure patients when they are on  regular dialysis, but  several other factors 
have been found to contribute to them. After renal transplantation, the addition 
of immunosuppressive treatment and the presence of renal rehabilitation causes 
other abnormalities of lipid transport . 
         Since hyperlipidemias become more pronounced as renal failure advances 
and can be modulated by therapeutic intervention  it is worthwhile to study and 
compare lipid profile abnormalities in renal failure patients on different modes 
of management. 
A prospective study was taken up, to study the lipid profile in patients of 
chronic renal failure 
   a. on conservative management 
    b. on regular haemodialysis 
    c. after renal transplantation and to compare with healthy controls. 
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AIM OF THE STUDY 
1. To estimate the levels of  
Serum triglycerides,  
Serum total cholesterol, 
          High  density lipoprotein cholesterol, 
Low density lipoprotein cholesterol, 
Ratio of total cholesterol to HDL cholesterol level in patients of chronic 
renal failure, 
a. On conservative management  
b. On regular hemodialysis 
c. Following renal transplantation 
2. To compare the lipid profile of the above mentioned patients  with that 
of healthy controls. 
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REVIEW OF LITERATURE 
PLASMA LIPIDS AND LIPOPROTEIN METABOLISM 
Plasma Lipids  
Lipids exist in the following forms: 
a. Fatty acids are straight chain compounds of varying lengths. 
b. Triglycerides consist of glycerol and three fatty acids. 
c. Phospholipids are complex lipids, resembling triglycerides but      
containing phosphate and a nitrogenous base. The major 
phospholipids   in plasma are lecithin and sphingomyelin. 
The phosphates and nitrogenous bases are water soluble, a fact that is 
important in lipid transport. Cholesterol has a steroid structure, and other 
steroids are derived from it. About 2/3rd of the plasma cholesterol is esterified 
with fatty acids to form cholesterol esters.  
Lipoproteins  
Lipids are relatively insoluble in water but are carried in the body fluids 
as soluble protein complexes known as lipoprotein : the water soluble (polar) 
group of protein, phospholipids and free cholesterol enclose a core of insoluble 
(non polar) cholesterol esters and triglycerides. They may be classified 
according to their densities using ultracentrifugation into four main classes. 
 
 5
Two classes are important for cholesterol transport : 
• HDL (High density lipoprotein) transports cholesterol from 
peripheral cells. 
• LDL (Low density lipoprotein) transports cholesterol to peripheral 
cells. 
Two classes are most important for triglyceride transport : 
• VLDL (Very Low Density Lipoproteins)  - transport endogenous 
triglyceride from the liver to the cells. 
• Chylomicrons transport exogenous (dietary) triglycerides from gut. 
A 5th Class, IDL (Intermediate Density Lipoprotein) is usually a transient 
intermediate in the metabolism of VLDL to LDL and contains both cholesterol 
and endogenous triglycerides. Plasma taken from a fasting subject contains 
HDL, LDL and VLDL. 
Chylomicrons    
Chylomicrons serve as the vehicle for the transport of dietary lipids in 
the plasma. They are produced within the enterocytes from the packaging of fat 
droplets (containing triglycerides, cholesterol ester, and phospholipids) with a 
number of apolipoproteins including apoB-48, apoA-I, apoA-II, and apoA-IV. 
The nascent chylomicrons are then released into the circulation via the 
lymphatic system. In the circulation, the nascent chylomicrons acquire apoE, 
apoC, and additional cholesterol from HDL-2 in exchange for apoA-I, apoA-II, 
and phospholipids. This transaction with HDL is essential for subsequent 
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lipolysis of chylomicrons by lipoprotein lipase (LPL) because apoE is 
necessary for chylomicron binding to the endothelial surface and apoC-II is 
required for activation of LPL. On reaching the capillary networks perfusing the 
muscle and adipose tissues, mature chylomicrons form a transient binding to the 
endothelial surface via their constituent apoE. The endothelium binding 
accommodates interaction of chylomicrons with the endothelium-bound LPL 
and its activation by apoC-II. This is followed by hydrolysis of the triglyceride 
content of chylomicrons and release of free fatty acids within the capillaries. 
The majority of fatty acids released diffuse into the adjacent myocytes for 
energy production or into adipocytes for energy storage. The remaining fatty 
acids are carried to distant sites by albumin and various lipoproteins. This 
results in formation and release of chylomicron remnants and return of the 
borrowed apoC and apoE to HDL before their eventual removal by the liver 
and other tissues via LDL receptor-related  protein (LRP).  
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VLDL, IDL, and LDL  
VLDL  particles are produced by the liver and serve as the vehicle for 
delivery of endogenous lipids to the peripheral tissues. Nascent VLDL is 
formed within the hepatocyte from the fusion of partially lipidated, newly 
synthesized apoB-100 with a triglyceride-rich lipid droplet, followed by 
addition of apoE, apoA-I, and apoA-II. The triglycerides and cholesterol ester 
used by hepatocytes for incorporation into VLDL are generated by the enzymes 
acyl-CoA diglycerol acyltransferase (DGAT) and acyl-CoA cholesterol 
acyltransferase (ACAT), respectively. The fatty acids and cholesterol supplies 
used for these processes by the hepatocyte are derived from a combination of 
de novo synthesis and uptake from the circulating blood.  After being released 
into the circulation, nascent VLDL acquires apoC and apoE from HDL-2 in 
exchange for apoA-I, apoA-II, and phospholipids.  
As with chylomicrons, this transaction with HDL-2 is critical for 
subsequent metabolism of VLDL by LPL and the VLDL receptor. On reaching 
the capillary beds perfusing the muscle and adipose tissues, mature VLDL 
particles bind to the endothelial surface via their constituent apoE. This process 
facilitates interaction of VLDL with LPL and the VLDL receptor. LPL, which 
is attached to the endothelial surface through its heparin-binding domain, is 
enzymatically activated by the apoC-II content of the adjacent VLDL. This is 
followed by hydrolysis of VLDL triglycerides by the activated enzyme, leading 
to release of two fatty acids. Most of the fatty acids released in this manner 
diffuse into the adjacent myocytes or adipocytes for energy production or 
storage, respectively. The remaining fatty acids bind to albumin and 
lipoproteins and are transported to the liver and other tissues. 
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 Lipolysis of VLDL by LPL results in a 70% reduction in their 
triglyceride content and detachment and release of a remnant particle, 
commonly known as IDL. In the circulation, IDL particles return the borrowed 
apoE and apoC to HDL and donate part of their remaining triglyceride cargo to 
HDL in return for cholesterol ester. The latter exchange is catalyzed by 
cholesteryl ester transfer protein (CETP). Most of the IDL particles undergo 
further lipolysis via hepatic triglyceride lipase. This leads to extraction of 
nearly all remaining triglycerides from IDL by the liver and formation of 
cholesterol-rich LDL, which are normally devoid of triglycerides. LDL 
particles are then removed via the LDL receptor by the liver, as well as 
extrahepatic tissues. The remaining IDL particles are removed by the liver (and 
other tissues) via LRP. The latter pathway is commonly referred to as the shunt 
pathway.  
An alternative pathway for clearance of VLDL has been recently 
identified, in which LDL is removed in its entirely by myocytes and adipocytes 
via binding to the novel VLDL receptor.1 
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HDL  
The primary function of HDL  is retrieval and transport of surplus 
cholesterol from the extrahepatic tissues for disposal in the liver2. This process 
which is commonly known as reverse cholesterol transport, is critical for 
cellular cholesterol homeostasis and protection against atherosclerosis, renal 
disease, and other complications. In addition, HDL plays a major role in 
metabolism of triglyceride-rich lipoproteins by serving as a donor and acceptor 
of apoC and apoE for the nascent and remnant chylomicrons and VLDL, a 
process which is vital in triglyceride metabolism. Moreover, HDL serves as a 
potent endogenous inhibitor of inflammation, platelet adhesion, and LDL 
oxidation3. 
The principal apolipoprotein constituents of HDL are apoA-I and apoA-
II, which are produced by the liver and intestine and secreted with VLDL and 
chylomicrons, respectively. On reaching the extracellular space, apoA-I and 
apoA-II dissociate from VLDL and chylomicrons (as phospholipid complexes) 
and coalesce to form nascent HDL. apoA-I constitutes 70% of HDL protein 
content. In addition to serving as the main structural constituent of HDL, apoA-
I serves as the activator of LCAT, which is essential for the HDL-mediated 
cholesterol retrieval from extrahepatic tissues. The second most abundant 
apolipoprotein constituent of HDL is apoA-II, which represents 20% of HDL 
protein content. In addition to its role as a major structural constituent of  HDL, 
apoA-II serves as an activator of hepatic lipase, which plays a central role in the 
removal of HDL-borne triglycerides by the liver. Once formed, nascent HDL 
acquires apoE-phospholipid and apoC-phospholipid complexes from either the 
available pool in the plasma or from chylomicron and VLDL remnants. The 
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assembly of these components leads to formation of a small cholesterol-poor 
discoid particle known as HDL-3.  
HDL-mediated removal of surplus cholesterol from extrahepatic tissues 
requires attachment of nascent HDL to the ATP binding cassette transporter 
type I (ABCA1) 4,5,6 binding to ABCA1 appears to trigger active transfer of 
phospholipids to nascent HDL, a step which is necessary for efficient 
translocation of free cholesterol from adjacent caveolae to the surface of HDL4. 
Free cholesterol reaching the surface of HDL is promptly esterified by LCAT. 
Due to its intense hydrophobicity, cholesterol ester formed on the surface of 
HDL immediately moves to the core of HDL, thus sustaining the favorable 
gradient for maximal cholesterol uptake by the maturing HDL.  
These observations illustrate the critical role of LCAT in the maturation 
of cholesterol-poor HDL-3 to spherical, cholesterol ester-rich HDL-2 and, 
hence, HDL-mediated reverse cholesterol transport. Once fully loaded, HDL-2 
dissociates from the binding site and returns to the bloodstream. While in 
transit, HDL-2 participates in a series of elaborate exchanges of apoproteins 
and lipids with the apoB-containing lipoproteins before reaching the liver. In 
the liver, HDL-2 forms a reversible binding with the HDL receptor (SRB-1), 
which facilitates simultaneous unloading of its cholesterol ester content, as well 
as hydrolysis and extraction of its fatty acid cargo by hepatic lipase. These 
events lead to transformation of HDL-2 to HDL-3, its detachment from SRB-1, 
and its return to the blood stream for recycling7.  These observations highlight 
the critical role of SRB-1 in HDL-mediated reverse cholesterol transport and 
hepatic lipase-dependent disposal of HDL-borne triglycerides in the liver.  
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Another significant pathway of cellular cholesterol efflux is the 
facilitated and passive diffusion of free cholesterol followed by its binding to 
albumin and subsequent transfer to HDL in the circulation. This phenomenon 
highlights the important role of albumin in reverse cholesterol transport4.  
 
APOPROTEINS 
 The route of metabolism of lipoprotein is determined by the apoproteins 
they carry. These proteins not only make the lipids water soluble, but are 
necessary for lipoproteins secretion by hepatic and intestinal cells and for 
recognition  by the cell surface receptors. They also activate the enzymes  
involved in lipoprotein metabolism. 
 The functions of the main group of apoproteins  are summarized in the 
table below: 
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The main Apoproteins  
Apoproteins 
 
Occurrence Known function 
A Chlomicrons/HDL Cofactor for LCAT(A-I) 
B Chylomicrons,VLDL,IDL,LDL Secretion of 
chylomicrons,VLDL/ 
binding of LDL to 
receptors 
C HDL,VLDL,IDL,Chylomicrons
(from HDL) 
Cofactor for lipoprotein 
lipase(C-II) 
D HDL Cholesterol ester transfer 
E HDL,VLDL,IDLchylomicrons 
(HDL) 
Binding of IDL and 
remnant particles to 
receptors 
 
SUMMARY OF LIPOPROTEIN METABOLISM 
 Lipids are derived from food (exogenous) or are synthesised in the body 
(endogenous). 
The fate of exogenous (dietary) lipids 
 Fatty acids and cholesterol  released by  digestion of dietary fat are 
absorbed into the intestinal mucosal cells where they are reesterified to form 
triglycerides and cholesterol esters. 
         These, together with phospholipids and apoproteins B(essential for 
secretion from the cell), and A, are secreted as chylomicrons into lymphatics 
and pass through the thoracic duct into the systemic circulaton. 
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        In the lymphatics and the blood, apoproteins C&E originating from HDL, 
are added to the chylomicrons. Most of the chylomicrons are metabolized by 
adipose and muscle tissue. 
 The enzyme lipoprotein lipase, located in capillary wall, is activated by 
apoproteins C-II and triglycerides in the chylomicrons are hydrolyzed to 
glycerol and fatty acids. The fatty acids are taken up by the fat on muscle cells 
or are bound to albumin in the plasma, and the glycerol enters the hepatic 
glycolytic pathway. As the chylomicron shrinks surface apoprotein A, and 
some apoprotein C, and phospholipids, are reincorporated into HDL . The short 
lived particles are compounds mainly of cholesterol and apoproteins B,C &E. 
They bind to specific receptors in the liver and are taken by hepatocytes where 
the protein is catabolised and the cholesterol released into the cells. At the end 
of this process dietary triglycerides have been delivered to adipose tissue and 
muscle and cholesterol to the liver. 
The fate of endogenous lipids  
 Triglycerides are synthesized in the liver from FFA derived from 
adipose tissue , if carbohydrate intake is high , FFA may be synthesized from 
excess glucose. These triglycerides, together with cholesterol synthesized in the 
liver or derived from chylomicron remnants, combine with apoproteins B&C to 
form VLDL, After Secretion into the blood, the VLDL takes up more 
apoproteins C, from HDL. This activates lipoprotein lipase on the capillary 
walls and the triglycerides like the exogenous triglycerides in chylomicrons are 
hydrolysed and removed from the plasma, leaving IDL. Some IDL is taken up 
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by the receptors in the liver, but the rest is converted to LDL, which consists 
almost entirely of cholesterol and apoprotein B. The mechanism and site of this 
conversions are not known.  
 The further metabolism of LDL is only partly understood but is of great 
importance in the development of atheroma. LDL is probably removed from 
the plasma by two pathways. In the first, after binding to specific receptors 
found on most cell membranes LDL is taken up by the cells and releases 
cholesterol which can be incorporated in the membranes. This cholesterol by 
feed back inhibition of early steps in cellular cholesterol synthesis and by 
reduction of the synthesis of LDL receptors on the surface, regulates the cell 
content of cholesterol. Probably most of the cholesterol needed by peripheral 
cells is derived from the liver. Some LDL, specially if plasma levels are high 
may also enter some cells by an unregulated, passive route. Some LDL may be 
taken up by hepatocytes. 
 Thus at the end of this process endogenous triglycerides have been 
delivered to peripheral cells for local energy requirements and endogenous 
cholesterol for membrane synthesis.  
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Lipoprotein Metabolism 
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PLASMA LIPIDS AND LIPOPROTEIN PROFILE IN CRF  
 Hypertriglyceridemia is the most common abnormality in adults and 
children with renal failure although the reported prevalence varies considerably 
in different populations.10,11,12,13,17,19 
 Triglycerides are usually elevated to moderate degree20. The plasma 
cholesterol level is normal except condition where there is pronounced 
hypertriglyceridemia. Since enrichment of triglycerides is seen in VLDL, IDL, 
LDL, HDL12,14, progression of renal insufficiency leads to marked increase in 
total triglycerides with increase in VLDL,LDL,HDL lipoprotein triglycerides.16 
 Redistribution of cholesterol from HDL to VLDL and IDL occurs even 
when the plasma cholesterol level are within normal limits11,12. Total 
cholesterol is slightly elevated due to increase in VLDL Cholesterol. The 
decreased level of HDL cholesterol indicates reduction in the HDL2 and HDL3 
sub-fractions (8). It has been reported in the recent past that patients with 
chronic renal failure have increased concentration of lipoproteins.15, 22 
 In cases of less advanced renal failure (but significant) the plasma 
triglyceride and cholesterol are normal, but minor changes in the lipid profile 
might be seen including an increase in LDL triglyceride level and decrease in 
HDL. 
APOLIPOPROTEIN PROFILE IN CRF 
 The abnormalities of lipid metabolism has also been observed in the 
protein moieties of lipoprotein, the apolipoproteins. In advanced renal failure, 
the plasma protein profile shows decreased concentration of apolipopotein A-I 
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and A-II, normal or slightly increased levels of apo-B and normal or decreased 
levels of apo E.12,22 The most important feature of plasma apolipoprotein 
profile is significant increase in concentration of apo C-III, together with less 
marked increase of apo C-I and apo C-II.11,12,17 Though the apo C-III levels 
usually correlate with triglyceride levels, increased concentration of apo C-III 
is also seen in normotriglyceridemic patients. The above mentioned alterations 
in renal failure results in decreased ratio of apo A-I/apo C-III, apoA-I/apo-B 
and an increased ratio of apoD-III/apoE. 11,22,17 
 The apoC-III ratio  is a useful means of evaluating the efficiency of 
processes responsible for the degradation of triglyceride rich lipoprotein 12. The 
low ApoC-III ratio found in CRF is more pronounced in hypertriglyceridemia 
than in normolipidemic patients. 11 
 Studies in the distribution of apolipoprotein in major lipoprotein density 
classes has shown a shift in the distribution of apolipoprotein B,C and E from 
HDL to VLDL and LDL with three fold increase of the apolipoprotein in 
VLDL and two fold increase in LDL.14 In addition to apo C and apo E the 
levels of apo A-I and apo A-II are also found to be reduced in HDL.12 
 Studies in the recent past have emphasized the importance of 
apolipoprotein as marker of dyslipoproteinemia showing that one can observe 
significant changes in the apolipoprotein profile of plasma and major 
lipoprotein density classes in early stages of renal insufficiency12. 
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 There is a marked reduction in the levels of apo A-I and apo A-II and 
elevation  in the levels of apo C-III in patients with glomerular filtration rate of 
15-60 ml/min.  
 Redistribution of apoB, apoC-III and apoE, which is characteristic 
feature of advanced renal failure could also be detected in early renal 
insufficiency 11 Guitz macher et al12 found that increased levels of apo C-III are 
found in patients with near normal renal function and that levels of 
apolipoprotein increase as renal function deteriorates. 
Summary of lipoprotein profile abnormality 
1. Increase in Total Triglycerides. 
2. Increase in VLDL and LDL, HDL triglycerides 
3. Slight increase of total cholesterol. 
4. Decrease in HDL Cholesterol 
Summary of apolipoprotein profile abnormality 
1. Decreased Apo A-I, Apo A-II 
2. Increased Apo C-III 
3. Decreased Apo –E 
4. Normal or increased levels of Apo B 
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Pathogenesis of Uremic Dyslipidemia 
 
 
Enzymes and pathways that are adversely affected in CKD are indicated in red  
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PATHOGENESIS OF URAEMIC DYSLIPIDEMIA 
Abnormalities in triglyceride metabolism 
I. DECREASED CATABOLISM 
A. Decreased activity of lipolytic enzymes 
1. Lipoprotein lipase due to 
• Insulin deficiency  
• Inhibitors in uraemic plasma 
• Reduced apo C-II/apo C-III ratio     
2. Hepatic Triglyceride lipase. 
3. Lecithin cholesterol acyl transferase (LCAT) 
B. Alteration of lipoprotein substrate 
C. Decreased carnitine level. 
D. Decreased beta oxidation of free fatty acids. 
E. Triglyceride enriched LDL  
F. Altered apolipoprotein composition 
G. Increased apo C-III/apo E in IDL,LDL. 
H.  Modification of lipoproteins. 
I. Decreased receptor and non-receptor mediated uptake of lipoprotein. 
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II.  INCREASED TRIGLYCERIDE PRODUCTION 
   a. Increased dietary carbohydrates 
b. Uptake from glucose due to immune resistance insulin 
c. Hyperinsulinemia 
 
 
Abnormalities in HDL Metabolism  
CRF is consistently associated with reduced plasma HDL cholesterol 
concentration, impaired maturation of cholesterol ester-poor HDL-3 to 
cholesterol ester-rich HDL-2, increased HDL triglycerides, and depressed 
plasma apoA-I. These abnormalities are primarily due to CRF-induced 
dysregulation of several important proteins, which are briefly described below.  
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LCAT: LCAT plays an important role in HDL-mediated cholesterol 
uptake from the extrahepatic tissues and, as such, serves as a main determinant 
of HDL maturation and plasma HDL cholesterol level. Thus LCAT deficiency 
can potentially account for diminished plasma HDL cholesterol and impaired 
HDL maturation in CRF. Plasma LCAT activity is consistently diminished in 
patients with ESRD.9,18,21  
This is accompanied by a significant elevation of plasma-free cholesterol 
and a marked reduction in plasma esterified cholesterol concentration, 
providing functional evidence for diminished LCAT-dependent cholesterol 
esterification . The reduction in plasma LCAT activity is associated with a 
parallel reduction in plasma concentration of immunodetectable LCAT and 
downregulation of hepatic LCAT gene expression. 24,40,46 
CETP: CETP mediates transfer of cholesterol ester from HDL to IDL in 
exchange for triglycerides. Thus a potential increase in plasma CETP can 
contribute to the CRF-associated reduction in HDL cholesterol ester and 
elevation of HDL triglycerides. In fact, according to a recent study, more than 
34% of hemodialysis-dependent patients were found to have high plasma CETP 
levels.41 The mechanism responsible for the reported elevation of CETP in 
ESRD patients is unknown and requires future investigation. The effect of CRF 
is amplified by proteinuria, which has been shown to increase synthesis and 
markedly raise plasma concentration of CETP.60 Thus plasma CETP is 
expectedly elevated in patients with heavy proteinuria and mild to severe renal 
insufficiency.  
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Hepatic lipase: Hepatic lipase catalyzes hydrolysis and removal of the 
triglyceride content of HDL. Thus hepatic lipase deficiency can potentially 
contribute to increased HDL triglyceride content. CRF results in pronounced 
hepatic lipase deficiency in humans and experimental animals. 26  
apoA-I and apoA-II: apoA-1 and apoA-II constitute the main structural 
constituents of HDL. In addition, apoA-I serves as the LCAT activator as well 
as ligand for the SRB-1 and HDL binding protein (ABCA1 transporter), 
whereas apoA-II serves as the hepatic lipase activator. Plasma concentrations of 
apoA-I and apoA-II are significantly reduced in patients with ESRD.61 Studies 
in animals with experimental CRF have demonstrated that the CRF-induced 
reduction in plasma apoA-I is due to downregulation of hepatic apoA-I gene 
expression.44 The reduction in plasma concentration of these important 
constituents can, therefore, contribute to both diminished plasma HDL 
concentration and impaired HDL function in CRF.  
SRB-1: Hepatic SRB-1 is the primary pathway for disposal of HDL-
borne cholesterol ester and triglycerides.7 Therefore, potential dysregulation of 
this protein can impact HDL metabolism. Heavy glomerular proteinuria has 
been shown to significantly reduce hepatic SRB-1 protein expression in 
experimental animals.25 In contrast, CRF per se, without heavy proteinuria, 
induced by nephrectomy, does not significantly change SRB-1 mRNA or 
protein abundance in the liver.44 However, concomitant heavy proteinuria and 
renal insufficiency may affect SRB-1 expression and hence, HDL-mediated 
reverse cholesterol transport.  
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ACAT:HDL-mediated cholesterol uptake from the extrahepatic tissues 
depends on deesterification of cholesterol esters contained in the intracellular 
vesicles and the resultant release of free cholesterol. This process is opposed by 
ACAT, which is the main enzyme for intracellular esterification of cholesterol. 
Therefore, a relative increase in ACAT activity can potentially limit HDL-
mediated cholesterol uptake and hence, contribute to the reduction in plasma 
HDL cholesterol and impaired maturation of HDL. Although the effect of CRF 
on ACAT expression and activity in the extrahepatic tissues is not known, CRF 
has been recently shown to markedly raise hepatic ACAT-2 mRNA and protein 
abundance, as well as total ACAT activity.30 The potential contribution of 
ACAT to the CRF-induced dysregulation of HDL metabolism was illustrated 
by a recent study which revealed that pharmacological inhibition of ACAT 
results in a dramatic shift in plasma cholesterol from apoB-containing 
lipoproteins to HDL with virtually no change in plasma total cholesterol in 
CRF animals. 34  
Abnormalities in Cholesterol Synthesis and Catabolism  
Plasma total cholesterol is usually normal or reduced and only 
occasionally elevated in patients with ESRD. However, plasma cholesterol is 
consistently, albeit mildly, elevated in the CRF rats. Plasma cholesterol 
concentration is primarily a function of its biosynthesis, catabolism (cholesterol 
conversion to bile acids), and tissue uptake. The effects of CRF on regulation of 
these pathways have been investigated in a very limited number of studies. The 
findings of these studies are summarized here.  
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Hydroxy-3-methylglutaryl-CoA reductase and cholesterol 7 -hydroxylase : 
HMG-CoA reductase is the rate-limiting enzyme for cholesterol 
biosynthesis. In a study  Pandak and associates36 found elevated hepatic HMG-
CoA reductase activity and 7 -hydroxylase activity, the rate-limiting enzyme 
for cholesterol catabolism and conversion to bile acids.36 CRF results in 
posttranscriptional upregulation of these hepatic enzymes.  
The LDL receptor: LDL receptor-mediated cholesterol uptake plays an 
important role in cholesterol homeostasis. Chronic renal insufficiency in the 
absence of heavy proteinuria does not alter hepatic LDL receptor gene 
expression or protein abundance.However, heavy proteinuria alone or in 
combination with chronic renal insufficiency results in acquired LDL receptor 
deficiency, which plays a central role in the genesis of the associated 
hypercholesterolemia. 32,46  
Low-Density Lipoprotein in CRF 
Elevated plasma LDL cholesterol concentration is common in nephrotic 
syndrome but is not a typical feature of patients with advanced CRF. There are, 
however, qualitative changes in LDL in patients with CKD and dialysis 
patients. The proportions of sdLDL and IDL, which are considered to be highly 
atherogenic, are increased. IDL and sdLDL have high affinity for macrophages, 
which promote their entry into the vascular wall to participate in the formation 
of foam cells and atherosclerotic plaques . 
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DYSLIPIDEMIA IN CRF PATIENTS ON HEMODIALYSIS   
 The distinctive features of the lipid profile in dialysis patients appear to 
be the presence of low concentrations of HDL cholesterol and increased 
triglycerides, but without, or slight elevations of LDL cholesterol. A low HDL 
cholesterol concentration imparts additional risk of coronary heart disease. 
Hypertriglyceridemia is due to decreased lipase which is due to depletion of 
enzyme pool induced by frequent heparinisation.   Plasma residence time of 
LDL and IDL is more than twice as long in  HD patients as in nonuremic 
individuals . This reduced catabolism, however, is masked by the decreased 
production of LDL, resulting in near-normal plasma levels of LDL. These 
changes are due to diets with high carbohydrate and lipid content, decrease in 
lipoprotein lipase, metabolic acidosis, use of high rather than low molecular 
weight heparin, medications, high glucose content of dialysate and L-Carnitine 
deficiency. 
HYPERLIPIDAEMIA AFTER RENAL TRANSPLANTATION 
 Hyperlipidaemia is a well-recognized complication of renal 
transplantation.  Risk factors in the transplant population for hyperlipidaemia 
include age, male sex, diabetes, hypertension,prednisone dose, graft 
impairment, obesity and anti-hypertensive therapy. Reported changes of serum 
lipids include an increase in triglycerides23, total cholesterol, as well as an 
increase in VLDL and LDLCholesterol contents . Kasiske and Umen27 found 
that the serum cholesterol concentration was raised in 27% of patients at 1 to 2 
years after transplantation, which occurred within 3-6 months after  
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transplantation in 82% of patients. They further found that 
hypertriglyceridemia occurred later in the post transplantation course than 
hypercholesterolemia and was present in only 15% of the patients. 
 Serum high density lipoprotein- cholesterol content has been reported to 
be low by some authors.23,27 However, when analysing HDL subfractions, 
HDL2 Cholesterol was actually lower in female , but not in male transplant 
recipients.33 
 Serum total apolipoprotein A levels –have been reported to be 
decreased28 or normal23 and serum total apo B level increased.31 Plasma lecithin 
cholesterol acyl transferase (LCAT) activities have been measured by Chan et 
al in allograft recipients before and after transplantation.13 He found that when 
LCAT activities were decreased in uremic state, they were fully corrected after 
successful transplantation. Elevated concentration of this enzyme after 
transplant probably increases the turnover of triglyceride rich lipoprotein. As to 
VLDL triglycerides removal kinetics, most renal transplant patients have an 
impaired capacity to remove these lipoprotein particles and therefore develop 
an increase in serum triglycerides.42 At the same time, serum total cholesterol 
and HDL  cholesterol levels are also increased. The defect for the cause of 
hypertriglycerdemia has been reported to be less severe in kidney transplant 
recipients than that of chronically uremic patients. Surprisingly, circulating 
lipase activities have not been found diminished in patients after renal 
transplantation. 
 Post-transplant hypercholesterolaemia is probably multifactorial in 
origin. Corticosteroids have almost certainly been implicated above all.8,48 But 
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since immunosuppressive therapy generally relies on several medication, it is 
difficult to incriminate corticosteroids alone . It must be however pointed out 
that hypercholeterolemia was observed in most renal transplant recipients in 
earlier  series  when  high does prednisone regimes were used (37,38). Gokal  
et al38 and Tiergan et al39 found that when the maintenance does of oral 
prednisone was progressively reduced to 10mg daily or  less, serum total 
cholesterol levels returned to normal values in the majority of patients. Steroid 
thereapy by providing insulin resistance has been attributed to contribute to 
these abnormalities 38,39,49. These abnormalities are also caused by increased 
hepatic secretions of VLDL triglyceride and decreased removal of triglyceride 
in peripheral tissue. Human studies have demonstrated diminished clearance 
rates for infused synthetic triglycerides after transplantation13 Whilst studies of 
endogenous VLDL triglyceride turnover have indicated, over production8 or a 
range of defective removal and over production42 as a cause for the 
hypertriglyceridemia. 
  Chan et al13 have found that the cumulative steroid dose is high in  
hyperlipidemic than in normlipaemic renal allograft recipients. They also 
demonstrated a significant positive correlation between serum triglycerides 
concentration and plasma immunoreactive insulin levels.  
  In this regard, it is interesting to note that in acute experiments in rats, 
the rate limiting enzyme of lipogenesis, acetyl co-A caboxylase and free fatty 
acid synthetase, increase after steroid administration.8  The rise in immune 
reactive insulin concentrations precedes the rise the concentration of these rate 
limiting enzymes and in alloxan diabetic rats no rise in acetyl Co.A 
carboxylase activity can be demonstrated.  
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 Chan at al have also shown in 19 renal allograft recipients that K2 
(fractional clearance rate of intralipid) correlated inversely with plasma 
immunoreactive insulin levels and that at a given K2 renal allograft recipient 
have higher serum triglyceride concentration  than do normal subjects, 
probably reflecting increased triglyceride production. Although triglyceride 
production has not been measured directly, the finding of high free fatty acid 
concentration and positive correlation between serum triglycerides and insulin 
would indicate that increase hepatic production of triglycerides is the 
predominant factor. 
 The immunosuppressive agent cyclosporine may also adversely 
influence plasma lipids, since both serum TG and cholesterol levels decrease 
after conversation to azathioprine therapy, eventhough HDL concentration does 
not change49 and hypertriglycerdemia  was more severe under cyclosporine-
prednisone treatment than under azathioprine-prednisone therapy.43 However, 
reduction or cessation of cyclosporine is often  accompanied by a fall in serum 
creatinine which itself has been found to positively correlate with serum 
Cholesterol or TG level.29 The later observation does not exclude an effect of 
cyclosporine by its own as strongly suggested by the prospective study done by 
Raine et al43. The mechanism of this effect of cyclosporine is presently 
unknown. It may relate to its high liophilicity49 since upto 80% of the drug is 
transportated in plasma by binding to lipoproteins, especially LDL and HDL. 
 Anti-hypertensive agents may also play a role in the increase of serum 
cholesterol levels. Thus the  beta blocker propanolol leads to a rise of HDL 
cholesterol and also of VLDL-TG37 such effects are shared less by 
cardioselective beta-blockers. The body weight gain which is often observed 
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after successful  renal transplantation could at least theoretically be implicated 
in the hypertriglyceridemia of graft-recipients, even if no direct correlation 
exists between weight gain and plasma lipids in the general population28 
Increased food intake leads to increased hepatic triglyceride production. This 
mechanism  appears to predominate over decreased peripheral triglyceride 
metabolism in such patients39 Interestingly, increased serum triglyceride levels 
correlated with an extensive relative body weight in renal transplant patients 
and also with serum creatinine, but not with steroid or cyclosporine dose. 
Summary of Lipid Profile Changes after Transplantation 
1. Increase in total cholesterol with increase in VLDL, and LDL 
cholesterol. 
2. Increase in Triglycerides. 
3. Decrease in HDL cholesterol 
DYSLIPIDEMIA IN INDIANS 
 Asian Indians have the highest rates of mortality and morbidity from 
CAD amongst all Ethnic groups. In Indian population CAD is often premature 
and runs a malignant course. CAD in Indians is present with relatively lower 
levels of lipids and lipoproteins. Raised levels of  triglyceride-low HDL, apo B 
and Lp(a) occur commonly. Low levels of apo A-I  have also been found. 
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Lipid levels in Indians : (Kaul et al)35 
Category LDL-C 
(mg/dl) 
Cholesterol 
(mg/dl) 
Triglycerides(mg/dl) 
Desirable <100 <150 <150 
Borderline 100-130 150-200 150-170 
High >130 >200 >170 
 
MANAGEMENT OF DYSLIPIDEMIA IN CRF 
The appropriate management of dyslipidemia plays an important role in 
the overall care of the patient with chronic and ESRD, and renal transplantation.  
It is important to recognize that dyslipidemia in the patient with chronic and 
ESRD, and renal transplantation require a different screening and management 
approach than other populations,47 as dyslipidemia may be secondary to 
different conditions, such as proteinuria, diabetic hyperglycemia, or drug-
induced, all of which require a distinctive management approach.47 
Additionally, patients who have progressed to advanced renal disease may have 
altered metabolism and elimination of lipid lowering medications, which would 
increase their risk for adverse effects to these agents.  
 
 
 32
The United States (US) National Kidney Foundation's Kidney 
Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice 
Guidelines for Managing Dyslipidemias in Chronic Kidney Disease -  
Pharmacotherapy Recommendations: 
Patients with chronic renal disease should be considered to be in the high 
risk category 
Evaluation of dyslipidemias should occur at presentation with chronic renal 
disease , following a change in kidney therapy modality and annually 
Drug therapy should be used for LDL levels of 100-129 mg/dl after 3 month 
of therapeutic life style change 
Initial drug therapy should be with a statin 
Fibrates may be used  in stage 5 CRF patients with triglyceride levels of 
>/=500mg/dl and for patients with triglyceride>/==200mg/dl and 
LDL>/==130mg/dl who do not tolerate statins. 
 
            Starting at a low dose and then titrating the dose of the statin upward to 
the goal minimizes adverse effects. Elevated transaminases occur in some 
patients on statin therapy and baseline values should be obtained. The risk of 
rhabdomyolysis from statins is low in general but it is increased in patients 
with chronic renal disease and those taking immunosuppressive agents, 
macrolide antibiotics, and fibric acid derivatives.50  
For patients with elevated triglycerides (>500 mg/dL), fibric acid 
derivatives and niacian may be used. Fibrates may increase the levels of stains; 
when used in combination an increased risk of rhabdomyolysis has been 
reported.50 Blood levels of a number of fibrates are increased in renal patients 
(e.g., bezafibrate, and fenofibrate), but levels of gemfibrozil are not increased. 
Elevations of BUN and creatinine have been reported with many fibrates. Since 
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this occurs only rarely with gemfibrozil, it has been recommended by some as 
the fibrate of choice in renal disease.  Niacin reduces lipids only to a moderate 
degree and may be associated with flushing and other untoward side effects. 
Bile acid sequestrants are effective in cholesterol lowering, but may interfere 
with the absorption of other medications. The potential benefit of combination 
therapy must be closely weighed against the increased risk of adverse effects. 
The pharmacotherapy management of posttransplant dyslipidemia is 
similar; however, another alternative which must be considered is the 
modification of the immunosuppressive regimen51 Examples of such 
modifications include switching from cyclosporine to tacrolimus, lowering 
doses of sirolimus, and corticosteroid withdrawal. Although studies that have 
examined these approaches have found no increased risk of graft rejection or 
dysfunction, it is important to keep in mind that many of these studies were not 
powered to detect such risk, and any modification in immunosuppressive 
therapy must be undertaken carefully and monitored closely.51 
Another important consideration in the pharmacotherapy management of 
posttransplant dyslipidemia is the potential drug interactions of lipid-lowering 
agents with immunosuppressants. Overall, statins have little effect on 
cyclosporine concentrations; however, cyclosporine has been shown to inhibit 
the metabolism of statins and a resultant increase in the risk of myopathy or 
rhabdomyolysis. 50,51 It has been suggested that fluvastatin, simvastatin and 
atorvastatin are the safest statins to be used with cyclosporine. Whereas fibrates 
may be especially valuable in patients treated with sirolimus, but should be 
carefully used in renal transplant patients taking cyclosporine or tacrolimus. 
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The Role of Statins 
Statin therapy has been found to rapidly improve vasomotor response, 
enhance coronary blood flow, and reduce the levels of adhesion molecules. 
This is due in part to the ability of the statins to increase endothelial nitric 
oxide production.52 The antioxidant effects of statins may also contribute to 
their ability to improve endothelial function. In addition, statins have been 
shown to exert positive effects on the fibrinolytic profile in the vascular 
endothelium54 and anti-inflammatory effects by several pathways, including the 
reduction of inflammatory markers such as C-reactive protein, modification of 
fibrosing factors such as TGF-beta, and a favorable effect on coagulation and 
plaque stability.52,53,55 Thus, theoretically, statins' anti-inflammatory and 
immunomodulatory effects and also their effects on endothelial function may 
be beneficial in renal hemodynamics. In addition, many large clinical trials 
have  confirmed the beneficial effect of lipid-lowering agents on preservation 
of kidney function.57 The protective effect on loss of renal function amounted 
to 1.9 ml/min/year, an effect whose magnitude was related to the length of 
treatment.  Therapy with newer lipid lowering agents, such as the statins, is 
relatively safe in patients with chronic renal disease. 
In the management of dyslipidemia after renal transplantation statins 
may have an additional benefit in the prevention of acute and chronic rejection. 
In the placebo-controlled ALERT (Assessment of Lescol in Renal 
Transplantation) study, 41 a total of 1050 patients were followed up for a mean 
of 5.1 years to evaluate the effect of fluvastatin on cardiovascular events. 
Fluvastatin proved to reduce the combined endpoint of cardiac death and 
nonfatal myocardial infarction by 35% (p =0.005). However, fluvastatin did not 
show a significant effect on noncardiovascular death or graft loss. 
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MATERIALS AND METHOD OF STUDY 
The study of lipid profile in patients of chronic renal failure was 
undertaken in The Department of Nephrology, Government Stanley Hospital, 
Chennai. 
SUBJECTS FOR THE STUDY 
• The study group constituted patients of  
a) Chronic renal failure  on conservative management 
b) Chronic renal failure on regular hemodialysis. 
c) Post Renal Transplantation with normal renal function. 
• The control group constituted  twenty healthy adults – 10 males and 
10 females of different age groups whose ages compared well with 
that of   study group. 
SELECTION OF CASES   
STUDY GROUP  
a. Patients with chronic renal failure on conservative management for a 
period of at least 6 months comprising of 10 males and 10 females 
within the age group of 15-50 years  with none of them having diabetes 
were taken up.   
b. Patients presenting with end stage renal failure on maintenance 
hemodialysis for period of 3 months comprising of 11 males and 9 
females, all falling within the age group of 15 years to 50 years were 
taken up and none of them had Diabetes . 
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c. Post transplant patients with normal renal functions comprising of 10 
males and 10 females within the age group of 15- 50 years and none of 
them had Diabetes. 
CONTROL GROUP 
This group consisted of 10 males and 10 females whose age group 
compared well with that of the study group. It was ascertained that none of 
them had hypertension, diabetes mellitus, renal or liver disease or any other 
metabolic disorder. 
 METHOD OF STUDY 
Estimation of lipid profile 
The various parameters analysed  were : 
¾ Serum total cholesterol  (TC) 
¾ Serum high density lipoprotein cholesterol (HDL) 
¾ Serum low density lipoprotein cholesterol (LDL) 
¾ Serum triglycerides  (TG) 
¾ Ratio of serum total cholesterol to high density lipoprotein 
cholesterol (TC/HDL). 
Samples were collected after a 12 hour fast to avoid post prandial rise in serum 
triglyceride level.  
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 Analysis of total cholesterol, triglycerides and HDL was done by use of 
an autoanalyser. Serum LDL cholesterol was calculated by Frederickson 
Friedwald’s formula according to which LDL=total cholesterol – 
(HDL+VLDL). VLDL was calculated as 1/5th of triglycerides. The results were 
statistically analysed. 
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OBSERVATIONS AND RESULTS 
TABLE – 1 
SERUM TOTAL CHOLESTEROL LEVEL IN DIFFERENT GROUPS 
AND THEIR COMPARISON (mg/dl) 
Group 
No.of 
cases 
Mean 
Standard 
deviation
'p'   
Value 
Significance 
Control 20 151.4 34.98 - - 
Conservative 
management 
20 155.2 31.4 0.72 NS 
Hemodialysis 20 159.3 38.8 0.503 NS 
Post  
transplant 
20 192.2 46.6 0.003 
Significant 
increase 
 
NS – Not significant 
 The table shows that the mean total cholesterol of the post transplant 
group is significantly high compared to other groups. 
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TABLE -2 
SERUM TRIGLYCERIDE LEVEL IN DIFFERENT GROUPS AND 
THEIR COMPARISON (mg/dl) 
Group 
No.of 
cases 
Mean 
Standard 
deviation 
'p'  
value 
Significance 
Control 20 113.9 43.3 - - 
Conservative 
management 
20 149.9 55.9 0.029 
Significant 
increase 
Hemodialysis 20 145.40 52.3 0.045 
Significant 
increase 
Post  
transplant 
20 158.4 48.3 0.004 
Significant 
increase 
 
NS – Not significant 
 The table shows that the serum triglyceride level is significantly high in 
all the three study groups when compared to controls. 
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TABLE – 3 
SERUM HDL CHOLESTEROL LEVEL IN DIFFERENT GROUPS AND 
THEIR COMPARISON (mg/dl) 
Group 
No.of 
cases 
Mean 
Standard 
deviation 
'p' 
value 
Significance 
Control 20 48.8 4.9 - - 
Conservative 
management 
20 37.5 3.0 0.001 
Significant 
decrease 
Hemodialysis 20 40.1 6.2 <0.001 
Significant 
decrease 
Post  
transplant 
20 39.2 4.4 <0.001 
Significant 
decrease 
 
 The table shows that the mean HDL cholesterol  is significantly 
decreased in all the three study groups. 
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TABLE – 4 
SERUM LDL CHOLESTEROL LEVEL IN DIFFERENT GROUPS AND 
THEIR COMPARISON (mg/dl) 
Group 
No.of 
cases 
Mean 
Standard 
deviation 
'p' value Significance 
Control 20 79.86 30.07 - - 
Conservative 
management 
20 87.8 34.92 0.44 NS 
Hemodialysis 20 90.1 40.78 0.371 NS 
Post  
transplant 
20 121.3 45.02 0.001 
Significant 
increase 
 
NS – Not significant 
 The table shows that the mean LDL cholesterol of the post transplant 
group is significantly high compared to other groups. 
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TABLE – 5 
RATIO OF SERUM TOTAL CHOLESTEROL TO HDL 
CHOLESTEROL IN DIFFERENT GROUPS AND THEIR 
COMPARISON  
Group 
No.of 
cases 
Mean 
Standard 
deviation
'p' value Significance 
Control 20 3.15 0.909 - - 
Conservative 
management 
20 4.2 1.1 0.002 
Significant 
increase 
Hemodialysis 20 4.01 1.0 0.007 
Significant 
increase 
Post  
transplant 
20 4.94 1.23 <0.001 
Significant 
increase 
 
NS – Not significant 
 The table shows that the ratio of total cholesterol to HDL Cholesterol is 
significantly high in all the three study groups. 
 
 
 
 47
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
To
ta
l  
C
ho
le
st
er
ol
 / 
H
D
L
Control Conservative
Management
Hemodialysis Post
transplant
Groups
Ratio of Serum Total Cholesterol to HDL Cholesterol in 
Different Groups and their Comparison
 48
TABLE – 6 
VALUES OF LIPID PROFILE  IN DIFFERENT GROUPS  
Total 
cholesterol 
Upto 200mg/dl 
(normal) 
200-239mg/dl 
(borderline-high) 
>240mg/dl 
(elevated) 
Control  18 1 1 
Conservative 
management 18 2 - 
CRF - HD 16 3 1 
Post transplant 12 5 3 
    
HDL <40 mg/dl 
(high risk) 
40-59mg/dl 
(moderate risk) 
>60mg/dl 
(low risk) 
Control  - 19 1 
Conservative 
management 14 6 - 
CRF - HD 11 8 1 
Post transplant 10 10 - 
    
LDL <100 mg/dl 
(normal) 
100-129mg/dl 
(borderline-high) 
>129mg/dl 
(elevated) 
Control  18 - 2 
Conservative 
management 14 5 1 
CRF - HD 13 4 3 
Post transplant 8 5 7 
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TABLE – 6 (CONTD.) 
VALUES OF LIPID PROFILE IN DIFFERENT GROUPS 
Serum triglycerides <150 mg/dl 
(normal) 
150-199mg/dl 
(borderlinehigh) 
>200mg/dl 
(elevated) 
Control  18 1 1 
Conservative 
management 11 5 4 
CRF - HD 14 1 5 
Post transplant 7 8 5 
    
TC/HDL RATIO <4 (normal) 4-6 (low risk) 
>6 
(high risk) 
Control  18 2 - 
Conservative 
management 9 9 2 
CRF - HD 13 6 1 
Post transplant 4 11 5 
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COMPARISON OF LIPID PROFILE BETWEEN MALES AND 
FEMALES 
TABLE – 7 
CONTROL GROUP 
Lipid profile Males Females Inference 
Total cholesterol 150.5 152.4 Not Significant 
Triglycerides 113.8 114.1 Not Significant 
HDL 48.9 48.8 Not Significant 
LDL 78.9 80.8 Not Significant 
TC/HDL 3.1 3.02 Not Significant 
 
TABLE - 8 
CONSERVATIVE MANAGEMENT GROUP 
Lipid profile Males Females Inference 
Total cholesterol 154.6 155.9 Not Significant 
Triglycerides 156.2 143.7 Not Significant 
HDL 38 37 Not Significant 
LDL 85.7 74.4 Not Significant 
TC/HDL 4.13 4.28 Not Significant 
 
 The above two tables show that there is no significant difference in the 
lipid profile between males and females in the control and the conservative 
management group. 
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COMPARISON OF LIPID PROFILE BETWEEN MALES AND 
FEMALES 
TABLE – 9 
HEMODIALYSIS GROUP 
Lipid profile Males Females Inference 
Total cholesterol 156 162 Not Significant 
Triglycerides 149 142 Not Significant 
HDL 40.3 40 Not Significant 
LDL 85.7 93 Not Significant 
TC/HDL 3.8 4 Not Significant 
 
TABLE – 10 
POST TRANSPLANT GROUP 
Lipid profile Males Females Inference 
Total cholesterol 193.2 191.3 Not Significant 
Triglycerides 148.2 168.6 Not Significant 
HDL 41 37.4 Not Significant 
LDL 122.5 120.1 Not Significant 
TC/HDL 4.7 5.1 Not Significant 
 
 The above two tables show that there is no significant difference in the 
lipid profile between males and females in the hemodialysis and the post 
transplant group. 
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SUMMARY OF THE OBSERVATION 
The lipid profile study of chronic renal failure patients on conservative 
management, on regular hemodialysis and post transplantation showed the 
following changes. 
1. SERUM TOTAL CHOLESTEROL 
The total cholesterol levels were normal in 18 (90%) and borderline high 
in 2(10%) patients in the conservative management group. The levels were 
normal in 16(80%), borderline high in 3(15%) and elevated  in 1(5%) in the 
hemodialysis (CRF – HD) group . In the post transplant group the levels were 
normal in 12(60%), borderline high in 5(25%) and elevated in 3(15%) patients. 
The mean total cholesterol in the control group was 151.45mg/dl, the 
conservative management group was 155.2mg/dl, CRF – HD group was 
159.3mg/dl and the post transplant group was 192.2mg/dl. The mean 
cholesterol was significantly increased in the post transplant group when 
compared to the other groups. 
2. LDL CHOLESTEROL 
The LDL cholesterol levels were normal in 14(70%) and borderline high 
in 5(25%) and elevated in 1(5%) patient in the conservative management group. 
The levels were normal in 13(65%), borderline high in 4(20%) and elevated in 
3(15%) in the  CRF – HD group. In the post transplant group the levels were 
normal in 8(40%), borderline high in 5(25%) and elevated in 7(35%) patients. 
The mean LDL cholesterol of the control group was 79.86mg/dl, the 
conservative management was 87.81mg/dl, CRF – HD group was 90.12mg/dl 
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and  the post transplant group was 121.37mg/dl. The mean LDL cholesterol 
was significantly increased in post transplant group when compared to the 
other groups. 
3. HDL CHOLESTEROL 
The HDL cholesterol levels were decreased in 14 (70%) and normal in  
6(30%) patients in the conservative management group. The levels were 
decreased in 11(55%) , normal in 9(45%) in CRF – HD group. In the post 
transplant group the levels were decreased in 10(50%) and normal in 10(50%) 
patients. The mean HDL cholesterol of the control group was 48.8mg/dl, 
conservative management group was 37.45mg/dl, CRF – HD group was 
40.15mg/dl and the post transplant group was 39.2mg/dl. HDL cholesterol was 
significantly decreased in all study groups when compared to controls. 
4. SERUM TRIGLYCERIDES 
The triglycerides levels were normal in 11 (55%) and borderline high in 
5(25%) patients and elevated in 4(20%) in conservative management group. 
The levels were normal in 14(70%), borderline high in 1(5%) and elevated  in 
5(25%) in CRF – HD group . In the post transplant group the levels were 
normal in 7 (35%) , borderline high in 8(40%) and elevated in 5(25%) patients. 
The mean triglyceride of the control group was 113.9mg/dl, the conservative 
management group was 149.9mg/dl, CRF – HD group was 145.4mg/dl and the  
post transplant group was 158.4mg/dl. The mean triglycerides level was 
significantly increased in all study groups when compared to controls. 
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5. RATIO 0F TOTAL CHOLESTEROL/HDL CHOLESTEROL 
The total cholesterol/HDL ratio were normal in 9 (45%) and borderline  
high in 9(45%) patients and high 2(10%) in conservative management group. 
The levels were normal in 13(55%) , borderline high in 6(30%) and elevated  in 
1(5%) in CRF – HD group . In the post transplant group the levels were normal 
in 4(10%) , borderline high in 11(55%) and elevated in 5(25%) patients. The  
total cholesterol/HDL ratio of control group was 3.15, conservative 
management  group was 4.21, CRF – HD group was 4.01 and the  post 
transplant group was 4.94. The TC/ HDL ratio was significantly increased in all 
study groups when compared to controls.  
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DISCUSSION 
 Serum lipid changes are encountered in a majority of patients with 
chronic renal failure. This is attributed due to abnormalities in lipoprotein 
metabolism. The major defect lies in the apoproteins which are the 
determinants of lipoprotein metabolism. The apoproteins have three major 
functions in lipoprotein metabolism. 1. They make the lipids water soluble. 2. 
They are necessary for lipoprotein secretion by hepatic and intestinal cells. 3. 
They activate the enzymes (lipolytic enzymes) involved in lipoprotein 
metabolism. Hence the abnormality in apoprotein leads to decreased catabolism 
of apo-B containing lipoprotein and  altered lipoprotein composition. Another 
factor which also plays a role is the changes in the action of insulin on lipolytic 
enzymes, possibly mediated via increased levels of parathyroid hormone in 
CRF. 
 The clinical consequences of defective lipoprotein transport which leads 
to renal dyslipoproteinemia may contribute to the development of 
atherosclerotic vascular disease and progression of glomerular and tubular 
lesions with subsequent deterioration of renal function. Dietary and/or 
pharmacologic intervention may ameliorate the uremic dyslipoproteinemia but  
the long term clinical effects of such treatment have yet to be established. 
Therapeutic interventions such as dialysis and renal transplantation seem to 
substantially modify the renal dyslipoproteinemia with several other factors 
contributing to the dyslipoproteinemia. 
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 This study was conducted to determine the lipid profile changes in 
chronic renal failure patients on conservative management, on regular 
hemodialysis and post renal transplant patients with normal renal function and 
to compare them with healthy controls. 
 The study population was 60 patients with 20 patients in each group and 
20 healthy controls. Each group had 10 males and 10 females to compare the 
sex variation, but there were 9 males and 11 females in the CRF –HD Group. 
 All the persons involved in the study were between 15-50 years. It was 
ensured that none of the control group had diabetes mellitus, hypertension, 
renal, liver or any metabolic disorder. It was also ensured that none of the 
patients in the study group had diabetes. 
 Serum total cholesterol , HDL cholesterol, LDL cholesterol , 
Triglycerides, Total cholesterol /HDL  cholesterol ratio were measured using 
an autoanalyser, after a 12 hour fast. The results were statistically analysed.  
Lipid changes in CRF patient on conservative management : reported 
studies 
1. The characteristic plasma lipid abnormality in CRF patients is moderate 
hypertriglyceridemia - this is due to impaired carbohydrate  tolerance 
leading to increased hepatic synthesis of VLDL and decreased activity 
of lipoprotein lipase and hepatic triglyceride lipase leading to decreased 
fractional catabolic rate of triglycerides. 
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2. Decrease in HDL cholesterol level -  this is due to the deficiency of 
LCAT which is essential for esterification of cholesterol. LCAT plays an 
important role in HDL mediated cholesterol uptake from the extra 
hepatic tissues and serves as a main determinant of HDL maturation and 
plasma HDL cholesterol level. Decrease in HDL level is also 
contributed by elevation of CETP. 
3. Normal or slightly increased total cholesterol level. 
4. Normal or slightly increased  LDL cholesterol level. 
Observation on lipid profile changes of CRF patients on conservative 
management showed the following results: 
 The mean age of the control group was 30.85 yrs and the conservative 
management group was 36.75 yrs. There was no significant difference in the 
lipid profile between the males and the females in the conservative 
management group. 
 The total cholesterol levels were normal in 90% and borderline high in 
10% of cases. The mean total cholesterol in the conservative management 
group was 155.2mg/dl and control was 151.4 mg/dl. This was not statistically 
significant. The triglyceride levels were  borderline high in 25% and elevated 
in 20%.The mean triglyceride level in the conservative management group was 
149.95mg/dl and was significantly increased when compared to a mean of 
113.95mg/dl in the control group. 
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 The LDL levels were normal in 70% and borderline high in 30% and 
HDL was <40mg/dl in 70%.The mean LDL cholesterol in the conservative 
management group was 87.81mg/dl and control was 90.12mg/dl. This 
difference was not significant. The mean HDL cholesterol in conservative 
management group was 87.81mg/dl and was significantly decreased when 
compared to the controls. The mean TC/HDL cholesterol ratio in conservative 
management group was 4.21 and was significantly increased compared to 
control . 
 The final results revealed a (1) significant decrease in HDL cholesterol 
(2) significant increase in triglyceride levels (3) significant increase in TC/HDL 
cholesterol ratio (3) non significant changes in serum total cholesterol and LDL 
cholesterol when compared to the control group. The significant decrease in 
HDL could be due to various reasons mentioned earlier (decrease in LCAT, 
hepatic lipase activity, increase in ACAT, decrease in apoA-I and apoAII) and 
the cause for hypertriglyceridemia has been mentioned earlier. Though the 
results were consistent with earlier studies the mean triglycerides and TC/HDL 
ratio were not as elevated as would be expected.  According to Bagdade et al10 
there was moderate hypertriglyceridemia and decrease in HDL levels in CRF 
patients.  
 Indian studies on lipid profile abnormalities in chronic renal failure 
(CRF) have varied from no abnormalities at all to significant abnormality 
(hypertriglyceridemia and reduced HDL) as described in the Western literature. 
Sharma et al62 and Kunde et al63 observed no hyperlipidemia in patients of CRF. 
On the other hand, Gupta and Das et al64 observed lipid abnormalities similar to 
those reported in Western studies. Though there is a significant increase in 
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triglycerides and TC/HDL ratio when compared to the controls, the mean level 
of triglycerides was < 150mg/dl and TC/HDL ratio was <6. This may be due to 
the study being conducted in low socioeconomic group whose dietary intake is 
low in both calories and fat and also due to the poor appetite in CRF patients. 
 Lipid changes in CRF patients on Hemodialysis : Reported studies  
1. Moderate increase in triglyceride levels 
2. Decrease in HDL levels 
3. Normal / slightly elevated total cholesterol, LDL cholesterol 
4. Increased Lp(a) 
5.  Increased apoB and apoA-IV and decreased apo A-I 
 In addition to factors responsible for renal dyslipoproteinemia the other 
contributing factors in a CRF-HD patient are   
1. Reduced lipolytic activity following repeated heparinisation. The 
exact reason is not understood but may be due to functional 
insulin deficiency or insulin resistance, and also due to the 
presence of non dialyzable factor of lipolytic enzyme (lipoprotein 
lipase), in the plasma of CHF-HD patients. The changes are more 
pronounced with the use of conventional heparin than low 
molecular weight heparin. 
2. The presence of Acetate in the dialysate which  gets converted to 
long chain fatty acids and later to cholesterol in the liver. 
3. Carnitine  deficiency where carnitine is necessary for fatty acid 
oxidation. 
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Observation on lipid profile changes of CRF- HD showed the following 
results 
 The mean age of the hemodialysis group was 29.5 yrs. There was no 
significant difference in the lipid profile between males and females in this 
group. 
 The total cholesterol levels were normal in 80% and elevated in 20% of 
cases. The mean total cholesterol in the CRF – HD group was 159.3mg/dl and 
control was 151.4mg/dl. This difference was not significant. The triglyceride 
levels were normal in 70% and elevated in 25%. The mean triglyceride level in 
the CRF – HD group was 145.50 and was significantly increased when 
compared to the  controls. 
 The LDL cholesterol levels were normal in 65% and borderline high in 
35% of patients in this group. The mean LDL cholesterol in the CRF – HD 
group was 90.12mg/dl and in the control was 79.86mg/dl. This difference was 
not significant. The HDL cholesterol levels were below 40 mg/dl in 55%.The 
mean HDL cholesterol in the CRF – HD group was 40.15mg/dl and was  
significantly decreased when compared to 48.8mg/dl in the control group. The 
TC/HDL ratio was elevated in 1 (5%) patient. The mean TC/HDL cholesterol 
ratio in CRF – HD group was 4.21 and was  significantly increased when 
compared to 3.15 in the control group. 
 The final results revealed  a (1) significant decrease in HDL cholesterol 
(2) significant increase in triglyceride levels (3) significant increase in TC/HDL 
cholesterol ratio (4) non significant changes in serum total cholesterol and LDL 
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cholesterol but the elevation in the mean triglyceride level and TC/HDL ratio 
was not as high as reported in Western and in some Indian studies. Variation  in 
lipid profile in hemodialysis patients in previous studies have not been 
consistent.  Shah et al65 have noticed hypertriglyceridemia in 11% of patients 
on hemodialysis. Zolezzi et al have noticed raised total cholesterol in 20%, 
decreased HDL in 50% and raised triglycerides in 45% of their patients on 
hemodialysis. Ibels et al8 have noticed decrease in triglyceride levels after 
dialysis. In this study, though the mean triglyceride level and TC/HDL ratio 
was increased compared to controls the levels were <150 mg/dl and < 6 mg/dl 
respectively. This may be due to poor appetite and dietary pattern low in 
calories and fat . 
Lipid changes in post transplant patients – reported studies 
 The characteristic pattern noted in earlier studies were  
(1) Increase in total cholesterol with increase in VLDL and LDL cholesterol 
(2) Increase in Triglycerides. 
(3) Decrease in HDL cholesterol 
 These changes are due to the improvement of diet, activation of LCAT, 
cumulative dose of steroids  and other immunosuppressive agents like 
cyclosporine and concomitant use of antihypertensives in the transplant 
recipients. 
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Observation on lipid profile changes of post transplant patients showed the 
following results 
 The mean age of this group was 25.7 yrs and there was no significant 
difference in the lipid profile between males and females. 
 The total cholesterol levels were borderline high in 25% and elevated in 
15% of the patients in this group.The mean total cholesterol in post transplant 
group was 192.2mg/dl and was significantly increased when compared to the 
controls which was 151.45mg/dl. The triglyceride levels were borderline high 
in 40% and elevated in 25%. The mean triglyceride level in the post transplant 
group was 158.4mg/dl and was significantly increased when compared to 
113.95mg/dl in the controls. 
The LDL levels were borderline high in 50% and elevated in 10% and 
HDL was decreased in 50% of the cases. The mean LDL cholesterol in the post 
transplant group was 121.37mg/dl and was significantly increased when 
compared to 79.86mg/dl in the controls. The mean HDL cholesterol in the post 
transplant group was 39.2mg/dl and was significantly decreased  when 
compared to the control group which was 48.8mg/dl. The mean TC/HDL 
cholesterol ratio in the post transplant group was 4.21 and was  significantly 
increased when compared to 3.15 in the controls  
The final results revealed a (1) significant increase in serum 
triglycerides (2) significant increase in total cholesterol (3) significant increase 
in LDL cholesterol (4) significant decrease in HDL cholesterol (5) significant 
increase in total cholesterol/HDL ratio when compared to the control group. As 
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mentioned earlier these changes are due to use of steroids , cyclosporine, 
improvement in diet and activation of LCAT after transplantation. These 
changes are similar to western studies. Shah et al65 have noticed 
hypercholesterolemia in 37.5% of transplant recipients. The mean cholesterol 
level was increased when compared to the controls but the elevation 
(192.2mg/dl) is not as high as expected which may be due to the poor 
socioeconomic status of the study group who mostly consume a low fat and a 
low calorie diet. 
 From this study it is inferred that dyslipidemias are common in chronic 
renal failure patients and especially more pronounced in transplant recipients. 
Since cardiovascular risk is excessive in patients with even minor renal 
dysfunction the same rationale of management should be applied as in the 
similar high risk population of diabetes. The  appropriate management  of 
dyslipidemia plays an important role in the overall care of the patient with 
chronic and ESRD and renal transplantation. Evaluation of dyslipidemias 
should occur at presentation with chronic renal disease, following a change in 
treatment modality and annually. Appropiate therapeutic life style change and 
drug therapy should be started. LDL level should be maintained below 
100mg/dl, Triglycerides below 150 mg/dl and HDL should be above 50. Drug 
therapy should be used for LDL levels of 130 mg/dl and also for LDL levels of 
100-129 mg/dl after 3 month of therapeutic life style change. 
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CONCLUSION 
¾ There is no significant difference in the lipid profile between males and 
females in the different groups. 
¾ On comparison with the control group  
♣ The mean total cholesterol is significantly increased in chronic 
renal failure patients after transplantation (p<0.001). 
♣ The mean triglyceride level is significantly increased in CRF 
patients on conservative management (p=0.029), on hemodialysis 
(p=0.045) and after transplantation (p=0.004). 
♣ The mean LDL cholesterol is significantly increased after 
transplantation (p=0.001). 
♣ The mean HDL cholesterol is significantly decreased in the 
conservative management group (p=0.001), the hemodialysis group 
(p<0.001) and in the post transplant group(p<0.001). 
♣ The total cholesterol to HDL cholesterol ratio is significantly 
increased  in CRF patients on conservative management (p=0.002), 
on hemodialysis (p=0.0007) and after transplantation (p<0.001). 
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¾ Due to increased prevalence of hyperlipidemia and its complications in 
chronic renal failure patients, early diagnosis of dyslipidemias is 
indicated and potential therapeutic approaches (therapeutic life style 
changes and pharmacotherapy) should be initiated to limit the long term 
consequences of cardiovascular disease in this population of patients, 
whose longevity is anticipated to increase with dialysis and 
transplantation. 
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